Oral GLP-1 receptor agonist semaglutide approved for cardiovascular risk reduction in Type 2 diabetes

The U.S. Food and Drug Administration approved the use of the oral glucagon-like peptide-1 receptor agonist semaglutide in patients with Type 2 diabetes at high risk of major adverse cardiovascular events, according to a news report from TCTMD.

In the Phase 3b SOUL trial, researchers found that the patients who received oral semaglutide in combination with standard care were less likely to experience nonfatal myocardial infarction, nonfatal stroke and cardiovascular mortality compared with placebo. They reported adverse gastrointestinal events as the most common cause of discontinuation in the oral semaglutide group.

Read more: TCTMD

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.